State-of-the-art treatments in non-Hodgkin's lymphoma

The non-Hodgkin's lymphomas are a diverse group of disorders morphologically, immunologically, and clinically. It is estimated that lymphoma represents 4% of the new cancer diagnoses and 4% of the cancer deaths. Lymphoma ranks third in increases in cancer death rates since 1973. Classification schemes have been further refined reclassifying previously described entities, differentiating B and T-cell entities, and defining new entities. This review will focus on standard treatment approaches, new therapeutic approaches, and preclinical directions.